-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Arrowhead Pharma, Raises Price Target to $126

Benzinga·07/23/2026 14:12:05
语音播报
Piper Sandler analyst Edward Tenthoff reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $110 to $126.